Inaugural BioPacific Partnering Forum

Date: May 8, 2016 @ 9:00 am – @ 5:00 pm
Location: Hanqi Investment Inc. at 1633 Bayshore Hwy, Unite 280, Burlingame, CA 94010

Inaugural BioPacific Partnering Forum

The 2016 BioPacific Conference brings together leaders in the life sciences community from the Pacific Rim and the United States. In order to further facilitate the interactions including project introduction and talent recruitment between our attendees and our sponsors, we are introducing BioPacific Partnering Forum in conjunction with our conference this year.

BioPacific Partnering Forum on May 8 Sunday (the next day after BioPacific Conference) for project collaboration and funding, and talent recruitment.

This is a complimentary event for BioPacific Conference attendees, sponsors and exhibitors.

Please use the link below to register. Registration is free.

https://docs.google.com/forms/d/1BQ_Q3GY53oyuOLYucsjPE_Df3IYxOU8ibRs-hPQXYKM/viewform

Agenda:

9-9:20am Networking

9:20-10:20am Featured presentations from three major sponsors regarding project collaboration and talent recruitment

· Ningbo Hangzhou Bay New Zone, 宁波杭州湾生命科技园（BioVillage）
· Zibo National High-tech Industrial Development Zone, 淄博高新区生物医药产业创新园
· Chengdu Kanghong Pharmaceuticals Group, 成都康弘药业集团股份有限公司

10:20-10:50am Brief presentations from other sponsors including Sekisui XenoTech, Paragon Genomics, JenKem Technology, Kelun Pharmaceutical 科伦药业, and more later

10:50am – 5pm Small group meetings or 1/1 discussions (may finish earlier than 5pm)

Information of three major sponsors:

1. 宁波杭州湾生命科技园（BioVillage）
a) “宁波杭州湾生命科技园（BioVillage）” 位于国家级经济技术开发区-宁波市杭州湾新区，在“东方巨龙”——杭州湾跨海大桥南岸，是上海、杭州、苏州等大城市的几何中心，长三角的明日之星。项目总投资56亿元，规划用地面积16.7公顷，将建成25万平方米集创业孵化楼、企业独栋、GMP中试实验室、分析测试平台、实验动物平台等组成的国际化、花园式生命科技园区。入园企业足不出户就可以在其个性化设计的服务平台上，获得从研发到产品上市全过程的所有配套设施支持和零距离、国际一流的专业化的技术服务。让入园者以更低的创业成本、更短的创业周期达成创业成功。园区同时预留稀缺的2000亩生物医药工业成熟用地，满足企业扩张用地的需求。

b) 项目，企业和人才需求

1) 项目：生物科技，生命健康等领域，包含但不限于生物医药，医疗器械，检验检测，生物环保，农业等领域的项目；

2) 成熟企业：拟在中国发展，落地，建立厂房，研究中心，工作机构，办事处等

3) 院所：拟在园区建立联合实验室，研究开发平台，产业转化平台等

4) 人才: 带项目或团队回国的生物技术类创业者人才。

2. 淄博高新区科技创新创业资源平台与创新技术需求

a) 淄博高新区生物医药产业创新园是国家生物医药产业基地, 设生物技术药物、天然药物、化学合成药物三个功能研发楼和中试车间，为生物医药项目开发与孵化提供完善的支持体系。公共技术服务平台一期建设占地4500㎡，拥有大中型仪器设备487台（套），仪器总投资5000余万元。平台下设药物分析测试中心、技术资料信息查询中心、生物技术药物实验室、化学合成药物实验室、天然药物实验室、药物制剂实验室和制药过程分析实验室（建设中）七个功能单元。山东大学淄博生物医药研究院的主要职责是平台运营、技术服务、成果转化与孵化、人才培养、交流合作。对外提供：技术服务资源共享、项目（技术）委托开发、成果转移-转化-孵化与市场推广等技术支持。
b) 技术和项目需求：生物医药、健康医疗、大数据开发与应用、新材料、先进制造、节能环保等领域为主；条件是以产业化为目标，科技含量高，技术成熟，市场前景较好，知识产权明晰无纠纷。

3. 成都康弘药业集团股份有限公司

a) 成都康弘药业集团股份有限公司是一家致力于中成药、化学药及生物制品的研发、生产、销售及售后服务的上市医药集团，总部位于中国四川省成都市，现有员工4000余人，拥有中成药、化学药和生物制品生产基地，销售网络遍布全国。在中枢神经系统、消化系统、眼科及其他等重点临床领域均有上市和处于研发阶段的创新产品，已申请和授权专利达到160余项（国外专利40项）。
b) 项目需求：在中枢神经系统、消化系统、眼科及其他等重点临床领域有知识产权的创新项目，尤其是满足临床需求的特色小分子化学制剂，创新生物大分子药物等，具体情况请面洽。
c) 人才需求：化学药物和生物大分子药物研发，生产工艺，质量控制，申报等领域的高端专业人才，具体情况请面洽。

Information of other sponsors including Sekisui XenoTech, Paragon Genomics, JenKem Technology, Kelun Pharmaceutical, Qilu Pharmaceutical and more

Sekisui XenoTech

Xenotech.com, 1101 West Cambridge Circle Dr., Kansas City, KS 66103

1. Sekisui XenoTech is a CRO with locations in Kansas, USA and Tokai, Japan, specializing in-vitro drug metabolism studies, many of which are required by the FDA an EMA in their ddi guidance documents for drug approval (reaction phenotyping, CYP inhibition, CYP induction, drug transport, metabolite ID, PPB, etc), in vivo AAALAC accredited ADME studies, a full line of drug metabolism products (microsomes, hepatocytes, etc), JCRB cell lines (~1200 cell lines), radiolabeled compound synthesis and metabolite generation.
2. Sekisui XenoTech would like to collaborate with new pharmaceutical companies to provide ADME and DMPK services or products.
3. Sekisui-XenoTech has a need for scientist experienced with Metabolite Identification.

Paragon Genomics: South San Francisco

1. Headquartered in South San Francisco, Paragon Genomics develops and commercializes fast, easy-to-use, and highly uniform multiplex PCR technology and products for targeted sequencing in the Next-Generation Sequencing (NGS) and precision medicine markets. Our CleanPlex™ technology employs a proprietary background cleaning mechanism that effectively removes non-specific PCR products generated during multiplex PCR reactions, dramatically improving the accuracy and speed of targeted sequencing. Our technology is applicable to many fast growing NGS segments such as cancer diagnostics, non-invasive prenatal testing (NIPT), inherited disease testing, liquid biopsy and personalized medicine.
2. Company Needs for Project Collaboration: Paragon Genomics is looking for Next Generation Sequencing labs that are interested in joining our early access customer program to apply CleanPlex™ to various segments of the fast growing molecular diagnostics and precision medicine markets. We also welcome discussions about potential opportunities to distribute our targeted sequencing reagent kits in selected geographical areas such as China, South America and Europe.
3. Recruiting Needs: bioinformatics specialists with experience in NGS bioinformatics pipeline and multiplex PCR assay design.

JenKem Technology USA Inc.

4105 W. Spring Creek Pkwy, #606B, Plano, TX 75024, U. S. A.

1. JenKem Technology specializes in the development and manufacturing of high quality polyethylene glycols (PEGs), monodisperse discrete PEGs, PEG co-polymers, custom PEG synthesis, and PEGylation services.
2. JenKem Technology offers high quality PEGs and PEGylation services to the pharmaceutical, biotechnology, medical device, diagnostics, and emerging chemical specialty markets, from laboratory through commercial GMP scale.
3. JenKem Technology is always looking for talent in research, manufacturing and analysis of polyethylene glycols at our Beijing and Tianjin sites, and for local talent in the Dallas Fort Worth area for our sales and marketing office.

Kelun Pharmaceutical

1. 科伦集团创立于1996年，现已发展成为拥有海内外90余家下属企业的现代化药业集团，是中国医药行业的领军型企业。集团旗下的科伦医贸和科伦药业（股票代码：002422）双双进入全国医药流通业和制造业前10强。2014年，集团营业收入超过350亿元，利税超过20亿元人民币。集团现有药物研发人员700余人，构建了以中央研究院（成都）为核心，以南方（苏州）、北方（天津）研究分院、海外（美国新泽西、圣地亚哥）研究分院为分支机构的集约化研究体系；致力于肿瘤、糖尿病、肝炎、心血管疾病等重大疾病领域的品牌仿制药、创新小分子、新型给药系统和生物技术药物的研发。
2. Talent recruitment: over 30 job positions in China and in the US in the above areas including innovative small molecule, biosimilar, etc.

More sponsors later